Report: CEOs detail 3 determining factors for healthcare success

A new report comprised of insights from healthcare CEOs highlights three specific factors necessary to compete in the ever-evolving medical industry.

The “Healthcare CEO Forum Report,” published by Huron Consulting Group, is the result of the company’s annual CEO forum, which brings together CEOs of hospital systems, academic institutions and community hospitals to discuss strategies for healthcare success.

“In the near-term, CEOs will need to focus on achieving clinical and operational efficiency as healthcare systems work to optimize cost and quality,” said Huron executive vice president Gordon Mountford via press release. “Leaders shared their insights and efforts to continue delivering the highest-quality, safest, most affordable care to their communities, knowing that the path forward will include new obstacles to overcome and new opportunities.”

The CEOs focused on three distinct success factors: advancing the transformation to value-based care, creating resilience among physicians and building interoperability among IT systems.

Read the press release and access the full report here.

 

John Hocter,

Digital Editor

With nearly a decade of experience in print and digital publishing, John serves as Content Marketing Manager. His professional skill set includes feature writing, content marketing and social media strategy. A graduate of The Ohio State University, John enjoys spending time with his wife and daughter, along with a number of surprisingly mischievous indoor cacti.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.